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gressed to severe marrow hypoplasia prior to undergoing a 4/6
HLA matched UCBT at 7 months of age. She was platelet and
packed red blood cell dependent as well as neutropenic. Prior to
cord blood transplant she had a number of bacterial infections, and
ultimately died on day 18 of overwhelming sepsis with Entero-
coccus gallinarum and extensive clotting of her descending aorta,
kidneys and pulmonary vasculature. The second child also showed
signs of throbocytopenia immediately after birth, and received
platelet transfusions prior to transplant. She had multiple infec-
tions with bacterial organisms. Her bone marrow showed minimal
megakaryocytes with initially normal cellularity, however prior to
UCBT her marrow cellularity started to decrease. Due to her
sisters disease progression, she underwent a 6/6 HLA matched
UCBT at 4 months of age. She engrafted on day 16. She had
complications including and early Candidal bacteremia, a seizure
and renal toxicity. She completely recovered and is currently more
than one year post transplant, well engrafted with full donor
chimerism and no evidence of GVHD. Following engraftment she
has not had further infections and appears to be developmentally
normal. Our two patients represent a variant of CAMT with
radio-ulnar synostosis lacking the HOXA11 mutation. We specu-
late they may have had an immune deﬁciency as evidenced by their
extensive infection history, which resolved after transplant in the
surviving child. Unrelated donor cord blood transplant appears to
be a curative option for these children, and proceeding to trans-
plant earlier may improve outcome.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS
GERM CELL TUMORS: LONG TERM FOLLOW-UP OF A MULTI-CENTER
EXPERIENCE
Doocey, R.1, Seftel, M.2, Barnett, M.1, Bredeson, C.2, Forrest, D.1,
Hogge, D.1, Lavoie, J.1, Nantel, S.1, Nevill, T.1, Shepherd, J.1,
Sutherland, H.1, Toze, C.1, Smith, C.1, Song, K.1 1. Division of
Hematology, Leukemia/Bone Marrow Transplant Program of British
Columbia, The Vancouver Hospital and Health Science Centre, Vancou-
ver, BC, Canada; 2. Manitoba Blood and Marrow Transplant Program
and CancerCare Manitoba, Winnipeg, MB, Canada.
High dose chemotherapy followed by autologous stem cell rescue
(autoSCT) has been used to provide long term disease control for
patients with poor prognosis germ cell tumors (GCT). Seventy-
one adult males from the Leukemia/BMT program of British
Columbia (n  54) and the Manitoba Blood and Marrow trans-
plant program (n  17) underwent autoSCT for GCT between
03/86 and 02/04. Median age at autoSCT was 31 years (range
16–58). Histological subtype included non-seminoma (n 67) and
pure seminoma (n  4). Fourteen patients presented with primary
extragonadal GCT involving mediastinum (n  11), retroperito-
neum (n  1), and central nervous system (n  2). Nine patients
proceeded straight to autoSCT after a suboptimal PR to induction
chemotherapy. The remaining 62 patients achieved acceptable
responses to initial therapy only to have clear evidence of relapsed
disease either by radiological or tumor marker progression. Dis-
ease status at the time of autoSCT was ﬁrst partial remission (n 
15), recurrent chemosensitive disease (n 51), recurrent chemore-
sistant disease (n  4), and recurrent untested disease (n  1). At
the time of autoSCT, tumor makers were normal in 44 patients
and elevated in 27 patients. High dose chemotherapy for patients
with nonseminomatous histology was etoposide 3.0 g/m2, carbo-
platin 0.8–1.2 g/m2, and ifosfamide 6.0 g/m2 or cyclophosphamide
7.2 g/m2. The 4 patients with pure seminoma received cyclophos-
phamide 7.2 g/m2 and carboplatin 1.5 g/m2. Stem cell source was
BM (n  38), PB (n  31), or both (n  2). At a median follow-up
of 7 years (range 1–18), 29 patients are alive and in remission.
Thirty-one patients have relapsed post autoSCT. The 5 year EFS
and OS for the entire 71 patients is 43% (95% CI 31-54%) and
44% (95% CI 32–55%), respectively. Extragonadal presentation
was associated with a signiﬁcantly reduced 5 year EFS (14% vs
50% P  .001) and OS (14% vs 51% P  .007). A completely
normal tumor marker remission at the time of autoSCT was
associated with a signiﬁcantly higher 5 year EFS (63% vs 14% P 
.001) and OS (63% vs 17% P  .001). The TRM at 5 years was
13% (95% CI 6%–22%). Four patients developed secondary ma-
lignancies post autoSCT. This retrospective review of a large
number of patients with extended follow up demonstrates auto-
SCT to be an effective treatment for patients with relapsed GCT
who can achieve tumor marker negativity. Extragondal presenta-
tions and failure to achieve a tumor marker negative remission
pre-autoSCT are associated with extremely poor outcomes.
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NON-VIRAL TRANSFECTION OF IMMATURE DENDRITIC CELLS WITH
GD2 mRNA ELICITS AN ALLOGENEIC IMMUNE RESPONSE
Stephan, B.1, Horvat-Switzer, R.1, Kletzel, M.1,2 1. Children’s Memo-
rial Research Center, Chicago, IL; 2. Northwestern University, Chicago,
IL.
Vaccination with tumor antigen-loaded Dendritic cells (DC) has
been shown to induce a CD4 T helper cell (Th1) response. The
purpose of this study is to develop a non-viral method of
transfecting DC with mRNA encoding for GD2 and measure
the difference between autologous and allogeneic Th1 response.
Immature DC were generated from CD14 cells from human
peripheral blood in RPMI media containing 10% fetal bovine
serum, 1X pen-strep, granulocyte-macrophage stimulating fac-
tor (GM-CSF), and Interlukin-4 (IL-4). Immature DC were
characterized by ﬂow cytometry and were negative for CD14
and CD83, and positive for CD45, CD80, CD1a, CD86, HLA-
DR, and CD11c. Full length human 1,4 N-acetylgalactosami-
nyltranserfase was cloned into a GFP expression vector and
sequenced. GD2 mRNA was transfected into immature DC at
day 5 of culture using Qiagen Transmessenger. Transfection
efﬁciency was determined by GFP ﬂuorescence at 48 hours
post-transfection via ﬂow cytometry. DC transfected with water
were used as a negative control. Cells were further matured with
tumor necrosis factor 
 (TNF 
) for an additional 24 hours
post-transfection. T cells were plated in 24 well plates and
co-cultured with autologous or allogeneic GD2 mRNA trans-
fected DC to prime the T cells. On day 8 of culture, the T cells
were restimulated, and T cell response against antigen loaded
DC, or water, was measured by the amount of IFN&gamm;
secreted using Elispot. The number of spots in each well were
counted and represent the amount of IFN&gamm; secreted by
Th1 cells. Of the GFP-positive transfected cells, 33% (range
31.4–35.0) expressed GD2 on the surface by ﬂow cytometry.
The amount and intensity of IFN secreted was signiﬁcantly
increased in mRNA transfected wells (mean of 31.13, range
3–60 spots) compared to water (mean of 16.38, range 3–36
spots). In addition the IFN secreted by individual T helper
cells was signiﬁcantly higher in the allogeneic transfected wells
(mean of 47.5, range 30–57 spots) versus the autolgous wells
(mean of 16.5, range 3–28 spots). These data demonstrate that
we are able to transfect DC with GD2 mRNA using a non-viral
method and elicit an allogeneic immune response in vitro.
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GRAFT-VERSUS-BRAIN TUMOR EFFECT IN A CHILD WITH ANAPLASTIC
ASTROCYTOMA AFTER CORD BLOOD TRANSPLANTATION FOR THERA-
PY-RELATED LEUKEMIA
Hudspeth, M.P.1, Cohen, K.1, Chen, A.R.1 1Sidney Kimmel Compre-
hensive Cancer Center at Johns Hopkins, Baltimore, MD.
The graft-versus-tumor effect has been described for several
solid tumors, but little is known regarding the susceptibility of
brain tumors to allogeneic immune responses. We report a case
of cord blood transplantation for therapy-related acute myelog-
enous leukemia in a 7-year old boy with active high-grade
astrocytoma lesions. This represents the ﬁrst reported case of a
pediatric patient undergoing transplantation for therapy-related
leukemia with a coexisting brain tumor. The patient received a
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preparative regimen consisting of busulfan, cyclophosphamide,
and anti-thymocyte globulin for a 5 out of 6 HLA-antigen-
matched unrelated donor cord blood transplant. Graft-versus-
host disease (GVHD) prophylaxis consisted of cyclosporine and
methylprednisolone, and the patient experienced isolated acute
skin GVHD. Notably, several astrocytoma lesions regressed or
decreased in size between 3 and 8 months after transplantation,
associated with a lymphocytic CSF pleiocytosis with elevated
CSF protein. The patient remains leukemia-free with stable
brain lesions 25 months after transplantation. This case illus-
trates the potential for donor-derived immune cells to control
brain tumors, and suggests that allogeneic bone marrow trans-
plantation may represent an important immunotherapeutic
strategy for the aggressive treatment of poor-prognosis brain
tumors. Future clinical protocols should seek to further charac-
terize the nature of the immune response to brain tumors after
allogeneic bone marrow transplantation.
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USE OF CHROMATIN MODIFYING AGENTS FOR EX VIVO EXPANSION OF
HUMAN UMBILICAL CORD BLOOD STEM CELLS
Hoffman, R.1, Hiroto, A.1, Mahmud, N.1 University of Illinois at
Chicago, Chicago, IL.
The ﬁxed number of hematopoietic stem cells (HSCs) within a
single cord blood (CB) unit has limited the use of CB for allogeneic
transplantation in adults. Efforts to promote self-renewal and ex-
pansion of HSCs have been met with limited success. Using pres-
ently available ex vivo culture techniques, HSCs lose their func-
tional properties in proportion to the number of cellular divisions
they have undergone. We hypothesized that chromatin modifying
agents, 5-aza-2-deoxycytidine (5azaD) and histone deacetylase
inhibitor, trichostatin A (TSA) could reactivate pivotal genes re-
quired for retaining the functional properties of dividing HSC to
permit transplantation of adults. A 12.5-fold expansion was ob-
served in the 5azaD/TSA treated CD34CD90 cell cultures
containing SCF, thrombopoietin, and FLT3 ligand (cytokines) in
comparison to the input cell number. Despite 9 days of culture,
35.4%  5.8% (n  10) of the total cells in the cultures exposed to
chromatin modifying agents were CD34 CD90 compared to
1.40%  0.32% in the culture containing cytokines alone. The
CD34CD90 cells were associated with a 9.8-fold increase in
the numbers of CFU-mix and 11.5-fold expansion of cobblestone
area-forming cells (CAFC). The frequency of SCID repopulating
cells (SRC) was 1 in 26,537 in primary CB CD34CD90 cells
but was increased to 1 in 2745 CD34CD90 cells following 9
days of culture in the presence of 5azaD/TSA resulting in a 9.6-
fold expansion of the number of SRC. In contrast, the cultures
lacking 5azaD/TSA had a net loss of both CFC/CAFC as well as
SRC. The expansion of cells maintaining CD34CD90 pheno-
type was not due to the retention of a quiescent population of cells
since all of the CD34CD90 cells in the culture had undergone
cellular division. CD34CD90 cells that had undergone 5–10
cellular divisions in the presence of 5azaD/TSA but not in the
absence still retained the ability to repopulate NOD/SCID mice.
We next assessed the effect of 5azaD/TSA treatment on the ex-
pression of HOX-B4, a transcription factor which has been impli-
cated in HSC self-renewal. A signiﬁcantly higher level of HOXB4
protein was detected by western blot analysis after 9 days of culture
in the cells treated with 5azaD/TSA as compared to cells exposed
to cytokines alone. The almost 10-fold increase in SRC achieved
using the chromatin modifying agents may be sufﬁcient to increase
the numbers of engraftable HSC within a single human CB unit for
adult recipients.
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ADULT HUMAN HEMATOPOIETIC CELLS DIFFERENTIATE INTO MATURE
T CELLS VIA A CD3-48- INTERMEDIATE WITHIN THE MOUSE THYMIC
MICROENVIRONMENT; A NEW MODEL SYSTEM FOR THE STUDY OF
HUMAN THYMOCYTE DEVELOPMENT FURTHER ENHANCED BY ANTI-
MURINE c-Kit mAB
Kraft, D.L.1, Czechowicz, A.1, Weissman, I.I.1 Stanford University
Depts of Pediatric Hematology/Oncology and Pathology, Stanford, CA.
Normal T cell differentiation occurs within the thymus. We
previously found that human thymocyte precursors develop via
a novel CD3-48- intermediate population, utilizing SCID-hu
thymic grafts (Kraft,Weissman,Waller;JEM). We have recently
worked to develop a more convenient robust model of human
hematopoiesis utilizing RAG2/Common Gamma Chain double
KO mice transplanted with hematopoietic progenitor cells from
adult human donors, and hypothesized that human engraftment
would be enhanced by selective inhibition of murine hemato-
poisis by administration of anti-murine c-Kit mAb. Methods:
Mobilized CD34 cells from healthy adults were obtained to
	90% purity by CliniMacs. 2–8  105 CD34 cells were
injected intrahepatically into newborn RAG2 DKO pups fol-
lowing 4Gy of irradiation. At serial time points, human CD45
chimerism was measured within the recipient marrow, blood,
spleen, liver, lymph node, and thymus. A subset of recipients
were treated with the anti-murine c-Kit mAb (ACK2) starting at
D 14. Results: Human engraftment was detectable in CD34
transplanted mice, and this was enhanced by suppression of
murine hematopoiesis by anti c-Kit mAb. Robust human thy-
mopoeisis was observed. A mean of 63% of cells within the
thymus were human derived. At earlier time points (4–6 weeks
post transplant) the recipient thymus were found to contain high
fractions of CD45CD348 cells (making up 30–40% of
human cells within the thymus) and the CD348 (20–30%)
and CD48 (30–70%) intermediate populations with very
rare mature CD348 or CD348 T cells. At later time
points the fraction of immature CD348 and CD348
populations declined and increasing populations of mature
CD348 and CD34-8 populations were identiﬁed in
distributions similar to a normal thymus. Conclusions: Human
T cell development appears to progress normally within a mu-
rine thymic microenvironment. The early development of a
CD348 intermediate suggests that T cell development
occurs via this population, unlike the CD348 intermediate
found in mice thymopoesis, suggesting that the pathway of
human T cell differentiation is intrinisic to the human thymo-
cytes, and is independent of whether the thymic stroma is
human or murine. This robust model system enabling study of
human thymopoesis utilizing hematopoietic stem cells from
normal and diseased adults human donors may provide signiﬁ-
cant advantages for the study of human intrathymic T cell
differentiation and function in vivo.
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CD8/TCR GRAFT FACILITATING CELLS ENHANCE HSC FUNCTION VIA
INDUCTION OF LOW LEVELS OF TNF-	
Ildstad, S.T.1, Rezzoug, F.1, Huang, Y.1, Wysoczynski, M.2,
Schanie, C.L.1, Ratajczak, M.Z.2, Fugier-Vivier, I.J.1 1. Institute for
Cellular Therapeutics, University of Louisville, Louisville, KY; 2. Stem
Cell Biology Program at James Brown Cancer Center, University of
Louisville, Louisville, KY.
Approaches to enhance engraftment of HSC when cell num-
bers are limiting remain an elusive goal in bone marrow trans-
plantation. We recently reported that CD8/TCR facilitating
cells (FC), a subpopulation of BM cells containing predomi-
nantly B220/CD11c/CD11b tolerogenic precursor-plasma-
cytoid dendritic cells, enhance HSC engraftment in allogeneic
recipients. FC are themselves tolerogenic, directly preventing
GVHD. Additionally, FC signiﬁcantly enhance engraftment of
limiting numbers of HSC in syngeneic recipients. In the present
studies, we investigated the mechanism of FC function. Here we
show for the ﬁrst time that FC signiﬁcantly increase HSC
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